The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Therapeutic Advances in the Treatment of Glioblastoma: Rationale and Potential Role of Targeted Agents
Open accessAbstract
Learning Objectives: After completing this course, the reader will be able to: Describe the genetic alterations frequently observed in GBM tumors as well as the cell signal transduction pathways that are aberrantly activated in these tumors.Discuss the clinical benefit recently associated with temozolomide chemotherapy for patients with GBM.Identify mediators of signal transduction pathways that are attractive targets of novel therapeutics in GBM patients.Understand the potential benefit associated with regionally administered therapies for GBM patients as a means to overcome drug delivery limitations into the central nervous system caused by the blood–brain barrier.Describe the rationale for combination regimens incorporating novel targeted agents for GBM patients. CME Access and take the CME test online and receive 1 AMA PRA category 1 credit at CME.TheOncologist.com
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib
Haas-Kogan, D. A., Prados, M. D., Tihan, T., Eberhard, D. A., Jelluma, N., Arvold, N. D., Baumber, R., Lamborn, K. R., Kapadia, A., Malec, M., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji161 · Cited by 465
Genetic pathways to glioblastomas
Ohgaki, H. (2005) · Neuropathology · doi:10.1111/j.1440-1789.2004.00600.x · Cited by 235
Cited by
Identification of noninvasive imaging surrogates for brain tumor gene-expression modules
Diehn, M., Nardini, C., Wang, D. S., McGovern, S., Jayaraman, M., Liang, Y., Aldape, K., Cha, S., & Kuo, M. D. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801279105 · Cited by 440
Lefranc, F., Facchini, V., & Kiss, R. (2007) · The Oncologist · doi:10.1634/theoncologist.12-12-1395 · Cited by 237
Liu, R., Li, J., Zhang, T., Zou, L., Chen, Y., Wang, K., Lei, Y., Yuan, K., Li, Y., Lan, J., et al. (2014) · Autophagy · doi:10.4161/auto.28912 · Cited by 178
Yanae, M., Tsubaki, M., Satou, T., Itoh, T., Imano, M., Yamazoe, Y., & Nishida, S. (2011) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-30-74 · Cited by 110
Metadata
- Authors
- Reardon, D. A., & Wen, P. Y.
- Venue
- The Oncologist
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-02-01
- Volume
- 11
- Issue
- 2
- Pages
- 152-164
- ISSN
- 1083-7159 (ISSN-L)
- 1549-490X
- OpenAlex
- W2106823541
- Cited by
- 231
- References
- 4
- FWCI
- 8.74
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Therapeutic Advances in the Treatment of Glioblastoma: Rationale and Potential Role of Targeted Agents. https://app.cochat.ai/papers/10.1634/theoncologist.11-2-152
- The paper
- Reardon, D. A., & Wen, P. Y. (2006). Therapeutic Advances in the Treatment of Glioblastoma: Rationale and Potential Role of Targeted Agents. The Oncologist. https://doi.org/10.1634/theoncologist.11-2-152
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
